Sinofn Health
Sinofn Health
Uruguay represents a sophisticated, albeit niche, market for Foods for Special Medical Purposes (FSMP). As the nation faces an aging demographic, the healthcare sector—led by the *Ministerio de Salud Pública (MSP)*—is increasingly prioritizing personalized nutritional intervention to manage chronic metabolic disorders and geriatric health.
Global trends in nutraceuticals are shifting toward "Precision Nutrition." In Uruguay, the demand for high-quality, scientifically-validated FSMP products is rising. Hospitals and pharmacies are seeking reliable partners who can offer more than just bulk supply—they require clinical efficacy, GMP-certified consistency, and regulatory compliance.
SINOFN bridges the gap between massive-scale manufacturing capacity and clinical-grade requirements. Our partnership with the Chinese Academy of Sciences ensures that every product—from PKU-specific formulations to ultra-energy protein admixtures—is built on a foundation of rigorous, peer-reviewed science, not just marketing claims.
Entering the Uruguayan market requires strict adherence to MERCOSUR standards. SINOFN provides full technical documentation, including stability testing, contaminant analysis (HPLC/GC-MS), and formulation transparency, making the regulatory pathway for our partners in Uruguay significantly smoother.
Our R&D team is spearheaded by Dr. Tan Shengjie (Peking University) and Dr. Zhang Ying (CAS Postdoc Fellow), supported by international expertise like Hans van Dijk. We don't just manufacture; we innovate.
10+ dedicated lines for gummies, powders, and clinical nutrition.
Advanced HPLC/GC-MS testing for total ingredient safety.
Pilot-scale prototyping for rapid market entry.
Yes. We provide complete technical dossiers, stability studies, and documentation required by local authorities to ensure a compliant market entry.
Our pilot-scale facility allows for rapid prototyping, typically within 4-6 weeks depending on ingredient complexity.
Yes, we offer tiered manufacturing solutions tailored to the volume and clinical requirements of both emerging brands and established healthcare enterprises.
